OncLive TV

Dr. Stacy Loeb on Screening Considerations in Prostate Cancer

June 28th 2016

Dr. Hughes on RT in Elderly Patients With ER+ Breast Cancer

June 28th 2016

Kevin S. Hughes, MD, co-director, Avon Comprehensive Breast Evaluation Center, medical director, Bermuda Cancer Genetics and Risk Assessment Clinic, Harvard Medical School, Massachusetts General Hospital, discusses treatment with radiation therapy for patients with ER-positive breast cancer.

The Impact of Lymphedema in Patients With Head and Neck Cancer

June 28th 2016

Jan S. Lewin, PhD, professor, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the impact of lymphedema in patients with head and neck cancer.

Dr. Gary Steinberg on New AUA Guidelines for Bladder Cancer

June 28th 2016

Dr. Muss on Assessing Treatment Response in Patients With Metastatic Breast Cancer

June 27th 2016

Hyman B. Muss, MD, School of Medicine, University of North Carolina (UNC)-Chapel Hill, Breast Cancer, Geriatric Oncology Program, Mary Jones Hudson Distinguished Professorship in Geriatric Oncology, discusses assessing treatment response in patients with metastatic breast cancer.

Dr. Andtbacka on Optimal Use of T-VEC in Melanoma

June 27th 2016

Robert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the optimal use of talimogene laherparepvec (T-VEC) in patients with melanoma.

Dr. Raghav on HER2 Amplification in Patients With CRC

June 24th 2016

Kanwal Raghav, MBBS, MD, assistant professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study examining HER2 gene amplification in patients with metastatic colorectal cancer.

Dr. Charles Ryan Discusses IMAAGEN Trial Update for Prostate Cancer

June 23rd 2016

Charles J. Ryan, MD, professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, provides an update to the IMAAGEN trial, which explored the effects of abiraterone acetate (Zytiga) and low-dose prednisone on prostate-specific antigen and radiographic disease progression in patients with nonmetastatic castration-resistant prostate cancer

Dr. Jorge Sierra on Risk Adapted Therapy in AML

June 23rd 2016

Dr. Wolchok on Updated CheckMate-067 Results for Melanoma

June 22nd 2016

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Department of Medicine and Ludwig Center at Memorial Sloan Kettering Cancer Center, discusses the updated findings from the CheckMate-067 trial, which explored nivolumab (Opdivo) combined with ipilimumab (Yervoy) in treatment-naive patients with advanced melanoma.

Dr. Mehra on KEYNOTE-012 Results of Pembrolizumab in Head and Neck Cancer

June 22nd 2016

Ranee Mehra, MD, chief, Head and Neck Hematology/Oncology, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the results of the KEYNOTE-012 study, which examined the efficacy of pembrolizumab (Keytruda) in patients with recurrent/metastatic head and neck squamous cell carcinoma.

Dr. Sartor on Mechanism of Action and Safety of Radium-223 in mCRPC

June 21st 2016

Oliver Sartor, MD, medical director of Tulane Cancer Center, discusses the mechanism of action of radium-223 dichloride (Xofigo) as well as its safety profile for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. John Byrd on Challenges in CLL

June 21st 2016

Dr. Yardley on HERMIONE-2 Trial for HER2+ Breast Cancer

June 20th 2016

Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the phase II HERMIONE-2 trial, which is a randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in patients with anthracycline-naive HER2-positive, locally advanced/metastatic breast cancer who were previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1).

Dr. Philip on Treatment Challenges for Patients With Soft Tissue Sarcoma

June 20th 2016

Tony Philip, MD, medical oncologist, Monter Cancer Center of the North Shore-LIJ Cancer Institute, assistant professor of Medicine, Hofstra-North Shore LIJ School of Medicine and NYIT College of Osteopathic Medicine, discusses treatment challenges for patients with soft tissue sarcoma.

Dr. Mark Kris on Immunotherapy and Frontline Options for Patients With NSCLC

June 18th 2016

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, explains what community oncologists need to know regarding immunotherapy and frontline treatment options for patients with non–small cell lung cancer (NSCLC).

Dr. Christian Gisselbrecht on Outcomes of Relapsed DLBCL

June 17th 2016

Christian Gisselbrecht, MD, a Professor of Haematology in the Haemato-Oncology Department of Hôpital Saint-Louis, at Diderot University, Paris, discusses refractory disease in aggressive diffuse large b-cell lymphoma (DLBCL).

Dr. Ahn on Link Between Tumor Somatic Variants and Chemo Resistance in Biliary Tract Cancer

June 16th 2016

Daniel H. Ahn, MD, assistant professor of Medicine, Mayo Clinic, discusses a next-generation sequencing survey of biliary track cancer to reveal the association between tumor somatic variants and chemotherapy resistance.

Jerome Galon on the Prognostic Value of Immunoscore

June 16th 2016

Jerome Galon, PhD, research director, Institut National de la Santé et de la Recherche Médicale, discusses the prognostic value of the Immunoscore assay and its corresponding validation study, which was presented during the 2016 ASCO Annual Meeting.

Dr. Overman on Nivolumab and Ipilimumab in Patients With MSI-H CRC

June 15th 2016

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study examining nivolumab (Opdivo) monotherapy, ipilimumab (Yervoy) monotherapy, and the combination of nivolumab and ipilimumab in patients with high microsatellite instability metastatic colorectal cancer.